Gout treatment halts coronary disease progression


Wednesday, 09 September, 2020


Gout treatment halts coronary disease progression

A multinational clinical trial has found that heart attacks and the need for coronary stenting or bypass surgery reduced by 30% in patients taking low-dose colchicine, an old and widely available drug commonly used to treat gout. The results are published in The New England Journal of Medicine.

The trial led by Perth GenesisCare cardiologists Professor Peter Thompson and Dr Mark Nidorf — in collaboration with the Dutch Network for Cardiovascular Research (WCN) in the Netherlands — confirmed that low-dose colchicine was safe, well tolerated over the long term and significantly reduced the risk of cardiovascular death, heart attack and ischemic stroke in patients with chronic coronary disease.

Professor Thompson, Deputy Director of Perth’s Harry Perkins Institute of Medical Research, said the trial involving almost 2000 WA patients and 3500 from the Netherlands found low-dose colchicine reduced the risk of heart attack and the need for stents or bypass surgery due to progressive angina.

“We found the benefits of colchicine therapy were seen soon after starting on the drug and continued to build over time. Over the course of the trial, colchicine was found to reduce the risk of cardiovascular death, heart attack and stroke by almost one-third,” Professor Thompson said.

Dr Nidorf was the first to demonstrate, seven years ago in a small trial of 500 patients, that low-dose colchicine might be beneficial in patients with coronary disease. The 2013 pilot trial generated several other trials around the world for conditions including heart attack and stroke. Trials in Sydney and Canada occurred for high-risk patients with coronary disease.

“It’s now understood that when cholesterol gets into the arterial wall it can spontaneously form into crystals which, like gout crystals, can incite a low-grade inflammatory response that causes chronic scarring of the artery,” Dr Nidorf said.

“When this inflammatory process is more acute it can lead to the breakdown of plaques, which can lead to heart attack and stroke.

“What we’ve been unable to do until now is reduce the inflammatory process that goes on inside the arterial wall.

”This is a groundbreaking, practice-changing result, because colchicine is inexpensive and widely available.

“We found it to be a profoundly powerful drug at low dose, with no danger signals associated with long-term use and excellent long-term tolerance.

“This medication does not come with the added cost of bleeding or lowering blood pressure, so it is a nice fit with current treatments and will likely form a cornerstone treatment in patients with coronary disease, alongside aspirin and statins.

“GenesisCare is delighted to partner with Perth’s Harry Perkins Institute of Medical Research and the Dutch Network for Cardiovascular Research to deliver the results of this international clinical trial, which will offer new hope to patients with coronary artery disease all over the world.”

Image caption: Dr Mark Nidorf and Professor Peter Thompson.

Related News

SHPA Virtual Congress award winners announced

The Society of Hospital Pharmacists of Australia (SHPA) has hosted a successful, celebratory and...

Monash superbug project to mobilise genomics, digital health and AI

The innovative project will integrate genomics, electronic healthcare data and AI technologies to...

Tool helps manage pain in dementia residents

A tech partnership means that carers can now access a tool to help identify, monitor and reduce...


  • All content Copyright © 2020 Westwick-Farrow Pty Ltd